Virus-like particle-based vaccines against hepatitis C virus infection

References

• Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902), 359–362 (1989).
   PubMed Web of Science ®Google Scholar
• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5(9), 558–567 (2005).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. PEGinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC et al. PEGinterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Kim JL, Morgenstern KA, Lin C et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87(2), 343–355 (1996).
   PubMed Web of Science ®Google Scholar
• Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11(7), 791–796 (2005).
   PubMed Web of Science ®Google Scholar
• Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 44(3), 527–535 (2006).
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56(Suppl. 1), S88–S100 (2012).
   Google Scholar
• Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138(2), 447–462 (2010).
   PubMed Web of Science ®Google Scholar
• Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT. Impact of PEGinterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study. Clin. Infect. Dis. 55(5), 631–638 (2012).
   PubMed Web of Science ®Google Scholar
• Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev. Vaccines 8(3), 333–345 (2009).
   PubMed Web of Science ®Google Scholar
• Alvarez-Lajonchere L, Duenas-Carrera S. Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development. Int. Rev. Immunol. 31(3), 223–242 (2012).
   PubMed Web of Science ®Google Scholar
• Lauer GM, Barnes E, Lucas M et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127(3), 924–936 (2004).
   PubMedGoogle Scholar
• Smyk-Pearson S, Tester IA, Lezotte D, Sasaki AW, Lewinsohn DM, Rosen HR. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J. Infect. Dis. 194(4), 454–463 (2006).
   PubMedGoogle Scholar
• Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J. Exp. Med. 209(1), 61–75 (2012).
   PubMedGoogle Scholar
• Spada E, Mele A, Berton A et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut 53(11), 1673–1681 (2004).
   PubMed Web of Science ®Google Scholar
• Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436(7053), 946–952 (2005).
   PubMed Web of Science ®Google Scholar
• Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302(5645), 659–662 (2003).
   PubMed Web of Science ®Google Scholar
• Shoukry NH, Grakoui A, Houghton M et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197(12), 1645–1655 (2003).
   PubMed Web of Science ®Google Scholar
• Pestka JM, Zeisel MB, Blaser E et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA 104(14), 6025–6030 (2007).
   PubMed Web of Science ®Google Scholar
• Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J. Infect. Dis. 205(5), 763–771 (2012).
   PubMed Web of Science ®Google Scholar
• Edwards VC, Tarr AW, Urbanowicz RA, Ball JK. The role of neutralizing antibodies in hepatitis C virus infection. J. Gen. Virol. 93(Pt 1), 1–19 (2012).
   PubMedGoogle Scholar
• Morin TJ, Broering TJ, Leav BA et al. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog. 8(8), e1002895 (2012).
   PubMedGoogle Scholar
• Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J. Hepatol. 54(6), 1273–1285 (2011).
   PubMed Web of Science ®Google Scholar
• Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 139(3), 965–974 (2010).
   PubMed Web of Science ®Google Scholar
• Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part one: advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin. Ther. Pat. 21(12), 1811–1830 (2011).
   PubMed Web of Science ®Google Scholar
• Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin. Ther. Pat. 22(4), 391–415 (2012).
   PubMed Web of Science ®Google Scholar
• Yu CI, Chiang BL. A new insight into hepatitis C vaccine development. J. Biomed. Biotechnol. 2010, 548280 (2010).
   Google Scholar
• Feinstone SM, Hu DJ, Major ME. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus. Clin. Infect. Dis. 55(Suppl. 1), S25–S32 (2012).
   PubMedGoogle Scholar
• Barnes E, Folgori A, Capone S et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 4(115), 115ra111 (2012).
   Google Scholar
• Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev. Vaccines 10(5), 659–672 (2011).
   PubMed Web of Science ®Google Scholar
• Farci P, Shimoda A, Wong D et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl Acad. Sci. USA 93(26), 15394–15399 (1996).
   PubMed Web of Science ®Google Scholar
• Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12(2), 190–197 (2006).
   PubMed Web of Science ®Google Scholar
• Puig M, Mihalik K, Tilton JC et al. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 44(3), 736–745 (2006).
   PubMedGoogle Scholar
• Law M, Maruyama T, Lewis J et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14(1), 25–27 (2008).
   PubMed Web of Science ®Google Scholar
• Meunier JC, Russell RS, Goossens V et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82(2), 966–973 (2008).
   PubMed Web of Science ®Google Scholar
• Pietschmann T, Kaul A, Koutsoudakis G et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl Acad. Sci. USA 103(19), 7408–7413 (2006).
   PubMed Web of Science ®Google Scholar
• Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J. Immunol. 188(8), 3724–3733 (2012).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10(11), 787–796 (2010).
   PubMed Web of Science ®Google Scholar
• Spohn G, Bachmann MF. Exploiting viral properties for the rational design of modern vaccines. Expert Rev. Vaccines 7(1), 43–54 (2008).
   PubMed Web of Science ®Google Scholar
• Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179(4), 2551–2555 (2007).
   PubMed Web of Science ®Google Scholar
• Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into virus like particles in insect cells. J. Virol. 72(5), 3827–3836 (1998).
   PubMed Web of Science ®Google Scholar
• Baumert TF, Vergalla J, Satoi J et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 117(6), 1397–1407 (1999).
   PubMed Web of Science ®Google Scholar
• Yu X, Qiao M, Atanasov I et al. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology 367(1), 126–134 (2007).
   PubMed Web of Science ®Google Scholar
• Kunkel M, Lorinczi M, Rijnbrand R, Lemon SM, Watowich SJ. Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. J. Virol. 75(5), 2119–2129 (2001).
   PubMedGoogle Scholar
• Blanchard E, Hourioux C, Brand D et al. Hepatitis C virus-like particle budding: role of the core protein and importance of its Asp111. J. Virol. 77(18), 10131–10138 (2003).
   PubMedGoogle Scholar
• Badia-Martinez D, Peralta B, Andres G, Guerra M, Gil-Carton D, Abrescia NG. Three-dimensional visualization of forming hepatitis C virus-like particles by electron-tomography. Virology 430(2), 120–126 (2012).
   PubMedGoogle Scholar
• Gastaminza P, Dryden KA, Boyd B et al. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J. Virol. 84(21), 10999–11009 (2010).
   PubMed Web of Science ®Google Scholar
• Triyatni M, Vergalla J, Davis AR, Hadlock KG, Foung SK, Liang TJ. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 298(1), 124–132 (2002).
   PubMedGoogle Scholar
• Triyatni M, Berger EA, Saunier B. A new model to produce infectious hepatitis C virus without the replication requirement. PLoS Pathog. 7(4), e1001333 (2011).
   PubMedGoogle Scholar
• Matsuura Y, Harada S, Suzuki R et al. Expression of processed envelope protein of hepatitis C virus in mammalian and insect cells. J. Virol. 66(3), 1425–1431 (1992).
   PubMedGoogle Scholar
• Luckow VA. Baculovirus systems for the expression of human gene products. Curr. Opin. Biotechnol. 4(5), 564–572 (1993).
   PubMedGoogle Scholar
• Grollo L, Torresi J, Drummer H, Zeng W, Williamson N, Jackson DC. Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes. Antivir. Ther. 11(8), 1005–1014 (2006).
   PubMedGoogle Scholar
• Torresi J, Fischer A, Grollo L, Zeng W, Drummer H, Jackson DC. Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T-helper epitopes. Immunol. Cell. Biol. 85(2), 169–173 (2007).
   PubMed Web of Science ®Google Scholar
• Torresi J, Stock OM, Fischer AE et al. A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology 45(4), 911–920 (2007).
   PubMed Web of Science ®Google Scholar
• Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 34(2), 417–423 (2001).
   PubMed Web of Science ®Google Scholar
• Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl Acad. Sci. USA 100(11), 6753–6758 (2003).
   PubMed Web of Science ®Google Scholar
• Barth H, Ulsenheimer A, Pape GR et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 105(9), 3605–3614 (2005).
   PubMed Web of Science ®Google Scholar
• Qiao M, Murata K, Davis AR, Jeong SH, Liang TJ. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology 37(1), 52–59 (2003).
   PubMed Web of Science ®Google Scholar
• Chua BY, Johnson D, Tan A et al. Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS ONE 7(10), e47492 (2012).
   Google Scholar
• Jeong SH, Qiao M, Nascimbeni M et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J. Virol. 78(13), 6995–7003 (2004).
   PubMed Web of Science ®Google Scholar
• Elmowalid GA, Qiao M, Jeong SH et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl Acad. Sci. USA 104(20), 8427–8432 (2007).
   PubMed Web of Science ®Google Scholar
• Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev. Vaccines 6(3), 381–390 (2007).
   PubMed Web of Science ®Google Scholar
• Borisova G, Arya B, Dislers A et al. Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen. J. Virol. 67(6), 3696–3701 (1993).
   PubMedGoogle Scholar
• Clarke BE, Newton SE, Carroll AR et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330(6146), 381–384 (1987).
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502), 2012–2018 (2005).
   PubMed Web of Science ®Google Scholar
• Hardy K, Stahl S, Kupper H. Production in B. subtilis of hepatitis B core antigen and a major antigen of foot and mouth disease virus. Nature 293(5832), 481–483 (1981).
   PubMed Web of Science ®Google Scholar
• Sominskaya I, Skrastina D, Dislers A et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin. Vaccine Immunol. 17(6), 1027–1033 (2010).
   PubMed Web of Science ®Google Scholar
• Ulrich R, Nassal M, Meisel H, Kruger DH. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv. Virus Res. 50, 141–182 (1998).
   PubMed Web of Science ®Google Scholar
• Yoshikawa A, Tanaka T, Hoshi Y et al. Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein. J. Virol. 67(10), 6064–6070 (1993).
   PubMedGoogle Scholar
• Wu CL, Leu TS, Chang TT, Shiau AL. Hepatitis C virus core protein fused to hepatitis B virus core antigen for serological diagnosis of both hepatitis C and hepatitis B infections by ELISA. J. Med. Virol. 57(2), 104–110 (1999).
   PubMedGoogle Scholar
• Mihailova M, Boos M, Petrovskis I et al. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 24(20), 4369–4377 (2006).
   PubMed Web of Science ®Google Scholar
• Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5(3), 215–229 (2005).
   PubMed Web of Science ®Google Scholar
• Schodel F, Moriarty AM, Peterson DL et al. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J. Virol. 66(1), 106–114 (1992).
   PubMed Web of Science ®Google Scholar
• Patient R, Hourioux C, Vaudin P, Pages JC, Roingeard P. Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. N. Biotechnol. 25(4), 226–234 (2009).
   PubMed Web of Science ®Google Scholar
• Bruss V, Gerhardt E, Vieluf K, Wunderlich G. Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Intervirology 39(1–2), 23–31 (1996).
   PubMedGoogle Scholar
• Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J. Virol. 75(5), 2130–2141 (2001).
   PubMed Web of Science ®Google Scholar
• Vietheer PT, Boo I, Drummer HE, Netter HJ. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir. Ther. 12(4), 477–487 (2007).
   PubMedGoogle Scholar
• Beaumont E, Patient R, Hourioux C, Dimier-Poisson I, Roingeard P. Chimeric HBV–HCV envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology doi:10.1002/hep.26132 (2012) (Epub ahead of print).
   Google Scholar
• Netter HJ, Woo WP, Tindle R, Macfarlan RI, Gowans EJ. Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine. Vaccine 21(21–22), 2692–2697 (2003).
   PubMedGoogle Scholar
• Canizares MC, Lomonossoff GP, Nicholson L. Development of cowpea mosaic virus-based vectors for the production of vaccines in plants. Expert Rev. Vaccines 4(5), 687–697 (2005).
   PubMed Web of Science ®Google Scholar
• Saini M, Vrati S. A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. J. Virol. 77(6), 3487–3494 (2003).
   PubMed Web of Science ®Google Scholar
• Tremblay MH, Majeau N, Gagne ME et al. Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. FEBS J. 273(1), 14–25 (2006).
   PubMedGoogle Scholar
• Rioux G, Babin C, Majeau N, Leclerc D. Engineering of papaya mosaic virus (PapMV) nanoparticles through fusion of the HA11 peptide to several putative surface-exposed sites. PLoS ONE 7(2), e31925 (2012).
   PubMedGoogle Scholar
• Denis J, Majeau N, Acosta-Ramirez E et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 363(1), 59–68 (2007).
   PubMed Web of Science ®Google Scholar
• Leclerc D, Beauseigle D, Denis J et al. Proteasome-independent major histocompatibility complex Class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. J. Virol. 81(3), 1319–1326 (2007).
   PubMed Web of Science ®Google Scholar
• Sandrin V, Boson B, Salmon P et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100(3), 823–832 (2002).
   PubMed Web of Science ®Google Scholar
• Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudoparticles containing functional E1–E2 envelope protein complexes. J. Exp. Med. 197(5), 633–642 (2003).
   PubMed Web of Science ®Google Scholar
• Sandrin V, Boulanger P, Penin F, Granier C, Cosset FL, Bartosch B. Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J. Gen. Virol. 86(Pt 12), 3189–3199 (2005).
   PubMed Web of Science ®Google Scholar
• Bartosch B, Cosset FL. Studying HCV cell entry with HCV pseudoparticles (HCVpp). Methods Mol. Biol. 510, 279–293 (2009).
   PubMedGoogle Scholar
• Bartosch B, Bukh J, Meunier JC et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl Acad. Sci. USA 100(24), 14199–14204 (2003).
   PubMed Web of Science ®Google Scholar
• Bonnafous P, Perrault M, Le Bihan O et al. Characterization of hepatitis C virus pseudoparticles by cryo-transmission electron microscopy using functionalized magnetic nanobeads. J. Gen. Virol. 91(Pt 8), 1919–1930 (2010).
   PubMedGoogle Scholar
• Garrone P, Fluckiger AC, Mangeot PE et al. A prime–boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci. Transl. Med. 3(94), 94ra71 (2011).
   PubMedGoogle Scholar
• Cocquerel L, Duvet S, Meunier JC et al. The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. J. Virol. 73(4), 2641–2649 (1999).
   PubMedGoogle Scholar
• Flint M, McKeating JA. The C-terminal region of the hepatitis C virus E1 glycoprotein confers localization within the endoplasmic reticulum. J. Gen. Virol. 80(Pt 8), 1943–1947 (1999).
   PubMedGoogle Scholar
• Buonocore L, Blight KJ, Rice CM, Rose JK. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J. Virol. 76(14), 6865–6872 (2002).
   PubMedGoogle Scholar
• Lagging LM, Meyer K, Owens RJ, Ray R. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J. Virol. 72(5), 3539–3546 (1998).
   PubMed Web of Science ®Google Scholar
• Matsuura Y, Tani H, Suzuki K et al. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 286(2), 263–275 (2001).
   PubMed Web of Science ®Google Scholar
• Huret C, Desjardins D, Miyalou M et al. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. Vaccine doi:10.1016/j.vaccine.2012.05.025 (2012) (Epub ahead of print).
   Google Scholar
• Kretzschmar E, Buonocore L, Schnell MJ, Rose JK. High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J. Virol. 71(8), 5982–5989 (1997).
   PubMedGoogle Scholar
• Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl Acad. Sci. USA 93(21), 11359–11365 (1996).
   PubMed Web of Science ®Google Scholar
• Fields BN, Hawkins K. Human infection with the virus of vesicular stomatitis during an epizootic. N. Engl. J. Med. 277(19), 989–994 (1967).
   PubMed Web of Science ®Google Scholar
• Johnson KM, Vogel JE, Peralta PH. Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am. J. Trop. Med. Hyg. 15(2), 244–246 (1966).
   PubMed Web of Science ®Google Scholar
• Barber GN. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 17(4), 516–527 (2004).
   PubMed Web of Science ®Google Scholar
• McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr. HIV Res. 1(2), 229–237 (2003).
   PubMedGoogle Scholar
• Ezelle HJ, Markovic D, Barber GN. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J. Virol. 76(23), 12325–12334 (2002).
   PubMed Web of Science ®Google Scholar
• Majid AM, Ezelle H, Shah S, Barber GN. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J. Virol. 80(14), 6993–7008 (2006).
   PubMedGoogle Scholar
• Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 292(2), 198–210 (2002).
   PubMed Web of Science ®Google Scholar
• Appel N, Zayas M, Miller S et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog. 4(3), e1000035 (2008).
   PubMedGoogle Scholar
• Masaki T, Suzuki R, Murakami K et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J. Virol. 82(16), 7964–7976 (2008).
   PubMed Web of Science ®Google Scholar
• Gouklani H, Bull RA, Beyer C et al. Hepatitis C virus nonstructural protein 5B is involved in virus morphogenesis. J. Virol. 86(9), 5080–5088 (2012).
   PubMedGoogle Scholar
• Kim M, Ha Y, Park HJ. Structural requirements for assembly and homotypic interactions of the hepatitis C virus core protein. Virus Res. 122(1–2), 137–143 (2006).
   PubMedGoogle Scholar
• Duenas-Carrera S, Vina A, Martinez R et al. Immunization with a DNA vaccine encoding the hepatitis-C-virus structural antigens elicits a specific immune response against the capsid and envelope proteins in rabbits and Macaca irus (crab-eating macaque monkeys). Biotechnol. Appl. Biochem. 39(Pt 2), 249–255 (2004).
   PubMed Web of Science ®Google Scholar
• Desjardins D, Huret C, Dalba C et al. Recombinant retrovirus-like particle forming DNA vaccines in prime–boost immunization and their use for hepatitis C virus vaccine development. J. Gene Med. 11(4), 313–325 (2009).
   PubMedGoogle Scholar
• Bellier B, Dalba C, Clerc B et al. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 24(14), 2643–2655 (2006).
   PubMedGoogle Scholar
• Bellier B, Huret C, Miyalou M et al. DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 27(42), 5772–5780 (2009).
   PubMedGoogle Scholar
• Diepolder HM, Gerlach JT, Zachoval R et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 71(8), 6011–6019 (1997).
   PubMed Web of Science ®Google Scholar
• Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97(10), 3171–3176 (2001).
   PubMed Web of Science ®Google Scholar
• Sarobe P, Lasarte JJ, Zabaleta A et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J. Virol. 77(20), 10862–10871 (2003).
   PubMed Web of Science ®Google Scholar
• Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437(7062), 1167–1172 (2005).
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Flechsig C, La Monica N, Tripodi M, Adler G, Dikopoulos N. Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes. J. Hepatol. 48(1), 51–60 (2008).
   PubMedGoogle Scholar
• Buonaguro FM, Tornesello ML, Buonaguro L. New adjuvants in evolving vaccine strategies. Expert Opin. Biol. Ther. 11(7), 827–832 (2011).
   PubMed Web of Science ®Google Scholar